EN DE
Watch Zenas BioPharma, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zenas BioPharma, Inc. (ZBIO) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Zenas BioPharma, Inc. stock $15.73, price $27.93, that is 43.7% below the price, quality 33 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US98937L1052

ZB Zenas BioPharma, Inc. logo Thin data Nov 17, 2026

Zenas BioPharma, Inc.

ZBIO · US

Far too expensive (fair value 44% below the price) and weak company.

Get notified free when this changes
Low debt 
Mixed Growth (revenue YoY +100.0 %/yr in USD) 
Insiders bought $1.0M (6M) 
Fair value $15.73 · Strongly overvalued 
Quality 33/100 
Negative free cash flow 
Trails peers (0/6) 
Narrow moat 5/100
Recent news very negative 
Thin data 
Estimate
Watch Zenas BioPharma, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$43.17 $6.43 Fair Value $15.73 Sep 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

26‑month range $6.43 – $43.17 · fair‑value band $11.79 – $19.66 · the $27.93 price screens above the $15.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Zenas BioPharma in your weekly email

Every Wednesday you see whether Zenas BioPharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.

Show moreShow less

Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.

The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody.

The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Stock analysis

Zenas BioPharma, Inc. (ZBIO) currently trades at $27.93, while our estimate is $15.73, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $11.79 (bear) to $19.66 (bull), the price of $27.93 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Zenas BioPharma, Inc. reported revenue of $10.0M in FY2025 versus $0 in FY2022. Reported net income was −$378M in FY2025.

Key figures

Market cap $1.9B Small · EPS (TTM) $−10.08 · Return on equity −265% · Return on assets (EBIT) −64.0% (4-year average) · Operating margin −759% · Revenue (TTM) $11.0M · Free cash flow −$172M · Net cash $30.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 35% below its 52-week high and 84% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −44%, ZBIO screens richer than that median.

Fair Value

Bear $11.79 Fair Value $15.73 Bull $19.66
Price $27.93 · Downside -43.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 97
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 45
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 27
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $1.0M, on May 18, 2026.

  • BuyLeon O Moulder JrChief Executive Officer, Director5× since Jan 7, 2026: 331,000 shares, avg. $17.41$5.8MMay 18, 2026
  • BuyHongbo LuDirector3× since Feb 11, 2026: 104,753 shares, avg. $20.57$2.2MMar 31, 2026
  • BuyTomas KiselakDirector150,000 shares at $20.00$3.0MMar 31, 2026
  • BuyPatricia L AllenDirector19,860 shares at $25.16$499,746Feb 13, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ZBIO screens overvalued: fair value 44% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (80 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Zenas BioPharma, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside −43.7% · Bottom 25%
Profitability
Return on assets −98.5% · Bottom 25%
Balance sheet
Debt / equity 0.08× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.79× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs ZBIO
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs ZBIO
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs ZBIO
argenx SE ARGX $950.95 $908.40 −4% vs ZBIO
CSL Limited CSL A$199.55 A$186.49 −7% vs ZBIO
Moderna, Inc MRNA $215.27 $135.64 −37% vs ZBIO
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs ZBIO
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs ZBIO
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs ZBIO
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs ZBIO

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zenas BioPharma, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zenas BioPharma, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ZBIO

Frequently asked questions

Is Zenas BioPharma, Inc. (ZBIO) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $15.73 versus a price of $27.93, about 44% lower (overvalued).
What is the fair value of ZBIO?
Our estimate for Zenas BioPharma, Inc. is $15.73 (as of Nov 17, 2026), built from audited fundamentals. The current price: $27.93.
What is the quality score of ZBIO?
Zenas BioPharma, Inc. has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zenas BioPharma, Inc. (ZBIO)?
Our calculated price target is the estimate of $15.73 (as of Nov 17, 2026). Cautious scenario $11.79, optimistic scenario $19.66. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Zenas BioPharma, Inc. stock forecast for 2026?
Our estimate puts fair value at $15.73, about 44% lower versus a price of $27.93 (overvalued). Cautious scenario $11.79, optimistic scenario $19.66. The calculation is refreshed regularly with new filings.
What is the revenue of Zenas BioPharma, Inc. (ZBIO)?
Zenas BioPharma, Inc. reported trailing-twelve-month revenue of about $11.0M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Zenas BioPharma, Inc. (ZBIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zenas BioPharma, Inc. it is $15.73 per share (as of Nov 17, 2026), against a price of $27.93.
Is Zenas BioPharma, Inc. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, ZBIO trades above its calculated fair value: price $27.93, fair value $15.73, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZBIO?
No. The price is what the market pays today ($27.93); the fair value is what the company's own numbers justify ($15.73). For Zenas BioPharma, Inc. the two are $12.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zenas BioPharma, Inc. worth?
The market values Zenas BioPharma, Inc. at about $1.9B (market capitalisation, as of Nov 17, 2026). Per share that is $27.93; our models calculate a fair value of $15.73 per share.
What do the bullish and bearish scenarios say about ZBIO?
Our models span a range for Zenas BioPharma, Inc.: cautious scenario $11.79, base $15.73, optimistic $19.66 per share (as of Nov 17, 2026, price $27.93). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zenas BioPharma, Inc. (ZBIO)?
Balance-sheet figures for Zenas BioPharma, Inc. (as of Nov 17, 2026): return on equity −265.1%, debt of 0.08 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is ZBIO from its 52-week high?
Zenas BioPharma, Inc. trades at $27.93, about 35% below its 52-week high of $43.17 and 84% above the low of $15.20 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $15.73 is for.
Which stocks are comparable to Zenas BioPharma, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zenas BioPharma, Inc. stock attractive at the current price?
The data as of Nov 17, 2026: price $27.93, calculated fair value $15.73 (−44%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Zenas BioPharma, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zenas BioPharma, Inc. (ZBIO)?
The closing price on Nov 16, 2026 was $27.93. Our estimate is $15.73, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zenas BioPharma, Inc. right now?
The price sits above even our optimistic bull case ($19.66). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Zenas BioPharma, Inc.

How large is the market capitalisation of Zenas BioPharma, Inc. (ZBIO)?
The market capitalisation of Zenas BioPharma, Inc. is $1.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Zenas BioPharma, Inc. (ZBIO)?
Earnings per share at Zenas BioPharma, Inc. are $−10.08. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Zenas BioPharma, Inc. (ZBIO)?
The return on equity (ROE) of Zenas BioPharma, Inc. is −265% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zenas BioPharma, Inc. (ZBIO)?
On an EBIT basis the return on assets of Zenas BioPharma, Inc. is −64.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zenas BioPharma, Inc. (ZBIO)?
The operating margin of Zenas BioPharma, Inc. is −759% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Zenas BioPharma, Inc. (ZBIO) generate?
The free cash flow of Zenas BioPharma, Inc. is −$172M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Zenas BioPharma, Inc. (ZBIO) hold?
Zenas BioPharma, Inc. holds more cash than debt, $30.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Zenas BioPharma, Inc. in the live analysis

One click puts Zenas BioPharma, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.